What is Entresto (Sacubitril/Valsartan)?

This post was written with Consensus AI Academic Search Engine - please read our Disclaimer at the end of this article. Entresto, a combination drug consisting of sacubitril and valsartan, is a significant advancement in the treatment of chronic heart failure with reduced ejection fraction (HFrEF). Approved by the US Food and Drug Administration (FDA) in 2015, Entresto has shown substantial benefits in reducing cardiovascular mortality and heart failure hospitalizations. This article delves into the composition, mechanism of action, clinical efficacy, and safety profile of Entresto.

Clinical Efficacy

The efficacy of Entresto was primarily demonstrated in the PARADIGM-HF trial, a large, randomized, double-blind study involving 8,442 patients with HFrEF. The trial showed that Entresto significantly reduced the incidence of death from cardiovascular causes or first hospitalization for worsening heart failure compared to enalapril, an angiotensin-converting enzyme (ACE) inhibitor3 6. Specifically, the hazard ratio for cardiovascular death was 0.80, and for death from any cause, it was 0.84, indicating a substantial survival benefit3.

Utilization and Prescribing Patterns

Despite its proven benefits, the uptake of Entresto in clinical practice has been slower than expected. Studies have highlighted that only a small proportion of patients receive the target maintenance dose, with even lower usage among the elderly population8. Factors contributing to this underutilization include concerns about the trial design, potential side effects, and the need for dose titration3 8.

Safety Profile

Entresto is generally well-tolerated, but it is associated with some adverse effects. The most common side effects include symptomatic hypotension, hyperkalemia, and renal dysfunction6 9. A post-marketing surveillance study confirmed the safety profile observed in clinical trials, with no new safety concerns identified9. However, cases of hyponatremia have been reported, particularly in elderly patients7.

Special Considerations

Entresto has also been studied in various other contexts, including its effects on kidney function and its potential benefits in conditions like lower urinary tract symptoms and erectile dysfunction associated with heart failure4 10. Additionally, its use in veterinary medicine has shown promise in managing heart conditions in dogs5. Learn more with Consensus: [button icon="📉" text="Did the PARADIGM-HF trial show that Entresto significantly reduces the incidence of cardiovascular death and heart failure hospitalizations?"][/button] [button icon="👩🏻‍🔬" text="Has the post-marketing surveillance of Entresto revealed any new safety concerns beyond those found in clinical trials?"][/button]

Entresto (Sacubitril/Valsartan) Composition and Mechanism of Action

Entresto is an orally administered supramolecular sodium salt complex that combines sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB)6. Sacubitril inhibits neprilysin, an enzyme responsible for the degradation of natriuretic peptides, thereby enhancing their beneficial effects such as vasodilation and natriuresis. Valsartan blocks the angiotensin II type-1 receptor, reducing the effects of angiotensin II, which include vasoconstriction and aldosterone secretion. Together, these actions help to alleviate the symptoms of heart failure and improve cardiovascular outcomes6. Learn more with Consensus: [button icon="🕸️" text="What is Entresto (sacubitril/valsartan) mechanism of action?"][/button] 

Adverse Effects of Entresto (Sacubitril/Valsartan)

Hypotension and Renal Dysfunction Hypotension and renal dysfunction are common adverse reactions, particularly within the first 30 days of treatment initiation2 3. These effects are significant enough to be listed as primary risks in the Risk Management Plan for the drug2. Hyperkalemia and Angioedema Hyperkalemia (elevated potassium levels) and angioedema (swelling under the skin) are also notable adverse effects, though less frequent than hypotension and renal dysfunction2 3. Involuntary Muscular Movements Cases of nonpainful, involuntary muscular movements (e.g., limbs and head) have been reported, which resolved upon discontinuation of the drug1. Hyponatremia There are reports of hyponatremia (low sodium levels) associated with the use of Entresto, particularly in elderly patients with heart failure4. Cognitive Dysfunction There is evidence suggesting that Entresto may increase the risk of memory and cognitive dysfunction, potentially exacerbating conditions like Alzheimer's disease5. Other Adverse Effects Additional adverse effects include cough, hypokalemia (low potassium levels), and cardiac decompensation3. Learn more with Consensus: [button icon="🔄" text="What are the adverse effects of Entresto (sacubitril/valsartan)?"][/button] [button icon="🩺" text="Is hypotension a common adverse effect of Entresto, especially in the first 30 days of treatment?"][/button]

How has Entresto (Sacubitril/Valsartan) Improved Patient Outcomes?

Improvement in Quality of Life (QOL) Sacubitril/valsartan has been shown to improve the quality of life in patients with HFrEF, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ). Patients on sacubitril/valsartan experienced larger improvements in KCCQ scores compared to those on ACE inhibitors or ARBs, with a higher likelihood of significant QOL improvement1 2. Reduction in Cardiovascular Death and Overall Mortality The PARADIGM-HF trial demonstrated that sacubitril/valsartan significantly reduced the risk of cardiovascular death and overall mortality compared to enalapril. The hazard ratio for cardiovascular death was 0.80, and for death from any cause, it was 0.84, indicating a substantial survival benefit3. Enhanced Cardiac Function and Reduced Ventricular Remodeling In patients with acute myocardial infarction (AMI), sacubitril/valsartan combined with percutaneous coronary intervention (PCI) improved cardiac function and prevented ventricular remodeling more effectively than irbesartan. This was evidenced by better recovery of left ventricular ejection fraction (LVEF) and improved results in the 6-minute walk test (6MWT)4. Reduction in Major Adverse Cardiovascular Events (MACE) The incidence of major adverse cardiovascular events was significantly lower in patients treated with sacubitril/valsartan compared to those treated with irbesartan, indicating better long-term cardiac outcomes4. Learn more with Consensus: [button icon="💆‍♂️" text="How has Entresto (sacubitril/valsartan) improved patient outcomes?"][/button] [button icon="💊" text="Does Entresto improve quality of life more significantly than ACE inhibitors or ARBs in patients with heart failure?"][/button]

Common Complaints Associated with Entresto (Sacubitril/Valsartan) Use

Hypotension: One of the most frequently reported adverse reactions to Entresto is hypotension, occurring within the first 30 days of initiation3. Renal Dysfunction: Renal impairment, including renal dysfunction and renal failure, is another common adverse reaction associated with Entresto use1 3. Hyperkalemia: Elevated potassium levels (hyperkalemia) have been noted as a significant adverse reaction in patients taking Entresto3. Angioedema: Although less common, angioedema has been reported as a serious adverse reaction in some patients3. Dehydration: Dehydration is also listed among the adverse reactions, though it is less frequently reported compared to other side effects3. Involuntary Muscular Movements: There have been case reports of nonpainful, involuntary muscular movements, such as abnormal limb and head movements, which resolved upon discontinuation of the drug1.  Learn more with Consensus: [button icon="🩸" text="Can Entresto cause elevated potassium levels, also known as hyperkalemia?"][/button] [button icon="💪" text="Have cases of involuntary muscular movements been reported in patients using Entresto, and do they resolve after discontinuation?"][/button]

Disclaimer

The content presented in this blog is generated by Consensus, an AI-powered academic search engine, and is based on publicly available scientific literature. While every effort is made to provide accurate, up-to-date, and well-researched information, the content is intended for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any decisions regarding medical conditions, treatments, or medications. The AI system's analysis may not cover all perspectives, emerging research, or individual cases, and it is not a substitute for professional expertise. Neither the blog publisher nor the developers of the AI-powered search engine are responsible for any actions taken based on the information provided in this content. Use of this information is at your own risk. Citations to the original scientific studies are included for reference, but these studies should be reviewed in full and interpreted with the guidance of a healthcare or research professional. If you are experiencing a medical emergency, please seek immediate attention from a healthcare provider.